PRME (Prime Medicine) Cash Flow from Others : $9.39 Mil (TTM As of Sep. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Prime Medicine Cash Flow from Others?

Prime Medicine's cash flow from others for the three months ended in Sep. 2024 was $14.64 Mil. Its cash flow from others for the trailing twelve months (TTM) ended in Sep. 2024 was $9.39 Mil.

Prime Medicine Cash Flow from Others Historical Data

The historical data trend for Prime Medicine's Cash Flow from Others can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Prime Medicine Cash Flow from Others Chart

Prime Medicine Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Cash Flow from Others

-4.60

98.42

17.68

11.79

Prime Medicine Quarterly Data
	Dec19	Dec20	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Cash Flow from Others	Get a 7-Day Free Trial											3.80	1.65	1.51	-8.41	14.64

Prime Medicine Cash Flow from Others Calculation

Cash Flow from Others for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $9.39 Mil.

Prime Medicine Cash Flow from Others Related Terms

Thank you for viewing the detailed overview of Prime Medicine's Cash Flow from Others provided by GuruFocus.com. Please click on the following links to see related term pages.

Prime Medicine Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Prime Medicine Inc (NAS:PRME) » Definitions » Cash Flow from Others

Comparable Companies

Traded in Other Exchanges

N/A

Address

21 Erie Street, Cambridge, MA, USA, 02139

Website

https://www.primemedicine.com

Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome and can treat a wide spectrum of diseases with high unmet medical needs and efficient and broad gene editing technology.

Executives

Robert Nelsen	director, 10 percent owner	8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Arch Venture Partners X, Llc	10 percent owner	8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Gv 2019 Gp, L.l.c.	10 percent owner	1600 AMPHITHEATRE PKWY, MOUNTAIN VIEW CA 94043
Jeffrey D Marrazzo	director	3737 MARKET STREET, SUITE 1300, PHILADELPHIA PA 19104
2019, L.p. Gv	10 percent owner	1600 AMPHITHEATRE PKWY, MOUNTAIN VIEW CA 94043
Alphabet Inc.	10 percent owner	1600 AMPHITHEATRE PARKWAY, MOUNTAIN VIEW CA 94043
Gv 2019 Gp, L.p.	10 percent owner	1600 AMPHITHEATRE PKWY, MOUNTAIN VIEW CA 94043
2021, L.p. Gv	10 percent owner	1600 AMPHITHEATRE PARKWAY, MOUNTAIN VIEW CA 94043
Gv 2021 Gp, L.l.c.	10 percent owner	1600 AMPHITHEATRE PARKWAY, MOUNTAIN VIEW CA 94043
Gv 2021 Gp, L.p.	10 percent owner	1600 AMPHITHEATRE PARKWAY, MOUNTAIN VIEW CA 94043
Thomas Cahill	director	PRIME MEDICINE, INC., 21 ERIE ST., CAMBRIDGE MA 02139
Keith Crandell	10 percent owner	8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Carman Alenson	officer: See Remarks	88 SIDNEY STREET, CAMBRIDGE MA 02139
Meredith Goldwasser	officer: SVP, Strategy & Corporate Ops.	PRIME MEDICINE, INC., 21 ERIE ST., CAMBRIDGE MA 02139
Jeremy Duffield	officer: Chief Scientific Officer	PRIME MEDICINE, INC., 21 ERIE ST., CAMBRIDGE MA 02139